National Cancer Institute of Canada
NCIC randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer.
PI: P. Hoskins Co: K. Swenerton, J. Pike, D. Miller, T. Ehlen

A phase III randomized study of Cisplatin alone versus a combination of etoposide, ifofamide, and cisplating(VIP) in the treatment of persistent, recurrent or advanced squamous or adnosquamous cell carcinoma of the cervix. (NCIC CX3)
PI: Co: T. Ehlen

National Cancer Institute of Canada
An international multi-centre randomized phase iii study comparing upfront debulking surgery versus neo-adjuvant chemotherapy in patients with stage IIIc or IV epithelial ovarian carcinoma
PI: T. Ehlen Co: M. Bertrand, P. Hoskins, U. Lee, L.A. Martin, D. Miller, J. Pike, K. Swenerton

National Cancer Institute of Canada
International randomized phase III trial of Paclitaxel/Epirubicin/Carboplatin (TEC) versus Paclitaxel/Carboplatin (TC) in the initial treatment of women with advanced ovarian cancer
PI: D. Swenerton Co: P. Hoskins, J. Benedet, M. Bertrand, T. Ehlen, D. Miller, J. Pike

Ampersand Medical Inc.
Clinical evaluation of InPath SBT system for adjunctive screening of cervical cytology specimens
PI: D. Miller Co: T. Ehlen

Ontario Clinical Oncology Group
Randomized trial of immediate treatment versus follow up of biopsy proven CIN I
PI: T. Ehlen Co: D. Miller, M. Bertrand, J. Benedet, L. Sadownik

A Phase II study to determine the efficacy and safety of ELINAFIDE as salvage therapy for patients with advanced carcinoma of the ovary
PI: K. Swenerton Co: T. Ehlen, P. Hoskins, D. Miller, M. Bertrand, J. Pike

National Cancer Institute of Canada
A comparison between BAY 12-9566 and placebo as consolidation after standard chemotherapy in patients with epithelial ovarian cancer
PI: M. Bertrand Co: T. Ehlen, P. Hoskins, D. Miller, J. Pike, K. Swenerton

A phase II, multicenter, non-randomized study of taxol in patients with ovarian cancer previously treated with platinum therapy.
PI: Co: T. Ehlen

Canadian Institutes of Health Research (CIHR)
PI: Coldman Co:

Terry Fox/CHUM
IICT/CHUM: A randomized controlled trial comparing routine colposcopy to HPV testing to identify persistent or recurrent high grade cervical cancer precursors (COHIPP)
PI: Mayrand Co: Ehlen

Merck Canada
A randomized international double-blinded, controlled with Gardasil, dose ranging, tolerability, immunogenicity and efficacy study of a multivalent human papillomavirus L1 virus-like particle vaccine adminstered to 16 – 26 year old women.
PI: Stuart Co: Ehlen

Inovio Pharmaceuticals
Phase 2 placebo-controlled study of VGX-3100 delivered IM followed by electrophoration with Cellectra-5P for the treatment of biosy-proven CIN 2/3 or CIN 3 with documented HPV 16 or 18
PI: Miller Co: Ehlen